Efficacy of rivastigmine in Alzheimer's disease patients with rapid disease progression: Results of a meta-analysis

Dementia and Geriatric Cognitive Disorders

Volumn 20, Issue 2-3, 2005, Pages 192-197

  Farlow, Martin R ^a   Small, Gary W ^b   Quarg, Peter ^c   Krause, Andreas ^c  

^a INDIANA UNIVERSITY SCHOOL OF MEDICINE   (United States)

^b UNIVERSITY OF CALIFORNIA   (United States)

^c NOVARTIS PHARMA AG   (Switzerland)

Author keywords

Alzheimer's disease; Cholinesterase inhibitor; Rapid progression; Rivastigmine

Indexed keywords

RIVASTIGMINE;

ALZHEIMER DISEASE; ARTICLE; CLINICAL TRIAL; COGNITION; DATA ANALYSIS; DISEASE COURSE; DRUG EFFICACY; HUMAN; LONGITUDINAL STUDY; META ANALYSIS; PRIORITY JOURNAL; RATING SCALE; REGRESSION ANALYSIS; RETROSPECTIVE STUDY; TREATMENT OUTCOME;

ALZHEIMER DISEASE; CHOLINESTERASE INHIBITORS; COGNITION; HUMANS; NEUROPROTECTIVE AGENTS; NEUROPSYCHOLOGICAL TESTS; PHENYLCARBAMATES; PSYCHOMOTOR PERFORMANCE; RANDOMIZED CONTROLLED TRIALS; TREATMENT OUTCOME;

EID: 23944514049     PISSN: 14208008     EISSN: None     Source Type: Journal    
DOI: 10.1159/000087301     Document Type: Article

References (24)

1. Rosenstein LD: Differential diagnosis of the major progressive dementias and depression in middle and late adulthood: A summary of the literature of the early 1990s. Neuropsychol Rev 1998;8:109-167.
2. Wiebusch H, Poirier J, Sevigny P, Schappert K: Further evidence for a synergistic association between APOE epsilon 4 and BCHE-K in confirmed Alzheimer's disease. Hum Genet 1999;104:158-163.
3. Lehmann DJ, Johnston C, Smith AD: Synergy between the genes for butyrylcholinesterase K variant and apolipoprotein E4 in late-onset confirmed Alzheimer's disease. Hum Mol Genet 1997;6:1933-1936.
4. Panegyres PK, Mamotte CD, Vasikaran SD, Wilton S, Fabian V, Kakulas BA: Butyrylcholinesterase K variant and Alzheimer's disease. J Neurol 1999;246:369-370.
5. Selkoe DJ: Alzheimer's disease: Genes, proteins, and therapy. Physiol Rev 2001;81:741-766.
6. Jacobs D, Sano M, Marder K, Bell K, Bylsma F, Lafleche G, et al: Age at onset of Alzheimer's disease: Relation to pattern of cognitive dysfunction and rate of decline. Neurology 1994;44:1215-1220.
7. Chui H, Lyness S, Sobel E, Schneider L: Extra-pyramidal signs and psychiatric symptoms predict faster cognitive decline in Alzheimer's disease. Arch Neurol 1994;51:676-681.
8. Stern Y, Tang M, Albert M, Brandt J, Jacobs DM, Bell K, et al: Predicting time to nursing home care and death in individuals with Alzheimer disease. JAMA 1997;277:806-812.
9. Doody RS, Massman P, Dunn JK: A method for estimating progression rates in Alzheimer disease. Arch Neurol 2001;58:449-454.
10. Hui JS, Wilson RS, Bennett DA, Bienias JL, Gilley DW, Evans DA: Rate of cognitive decline in Alzheimer's disease. Neurology 2003;61:1356-1361.
11. Farlow MR, Hake A, Messina J, Hartman R, Veach MS, Anand R: Response of patients with Alzheimer disease to rivastigmine treatment is predicted by the rate of disease progression. Arch Neurol 2001;58:417-422.
12. Corey-Bloom J, Anand R, Veach J: A randomized trial evaluating the efficacy and safety of ENA 713 (rivastigmine tartrate), a new acetylcholinesterase inhibitor, in patients with mild to moderately severe Alzheimer's disease. Int J Geriatr Psychopharmacol 1998;1:55-65.
13. Rösler M, Anand R, Cicin-Sain A, Gauthier S, Agid Y, Dal-Bianco P, et al: Efficacy and safety of rivastigmine in patients with Alzheimer's disease: International randomised controlled trial. BMJ 1999;318:633-640.
14. Schneider A, Anand R, Farlow M: Systematic review of the efficacy of rivastigmine for patients with Alzheimer's disease. Int J Geriatr Psychopharmacol 1998;1:S26-S34.
15. Anand R, Messina J, Hartman R: Dose-response effect of rivastigmine in the treatment of Alzheimer's disease. Int J Geriatr Psychopharmacol 2000;2:68-72.
16. Rosen WG, Mohs RC, Davis KL: A new rating scale for Alzheimer's disease. Am J Psychiatry 1984;141:1356-1364.
17. Folstein MF, Holstein SE, McHugh PR: 'Mini-Mental State': A practical method for grading the cognitive state of patients for the clinician. J Psychiatr Res 1975;12:189-198.
18. Mesulam M, Guillozet A, Shaw P, Quinn B: Widely spread butyrylcholinesterase can hydrolyze acetylcholine in the normal and Alzheimer brain. Neurobiol Dis 2002;9:88-93.
19. Perry EK, Perry RH, Blessed G, Tomlinson BE: Changes in brain cholinesterases in senile dementia of Alzheimer type. Neuropathol Appl Neurobiol 1978;4:273-277.
20. Ballard CG, Greig NH, Guillozet-Bongaarts AL, Enz A, Darvesh S: Cholinesterases: Roles in the brain during health and disease. Curr Alzheimer Res 2005, in press.
21. Wright CI, Geula C, Mesulam MM: Neurological cholinesterases in the normal brain and in Alzheimer's disease: Relationship to plaques, tangles and patterns on selective vulnerability. Ann Neurol 1993;34:373-384.
22. Perry E, McKeith I, Ballard C: Butyrylcholin-esterase and progression of cognitive deficits in dementia with Lewy bodies. Neurology 2003;60:1852-1853.
23. O'Brien KK, Saxby BK, Ballard GG, Grace J, Harrington F, Ford GA, et al: Regulation of attention and response to therapy in dementia by butyrylcholinesterase. Pharmacogenetics 2003;13:231-239.
24. Holmes C, Ballard C, Lehman D, David Smith A, Beaumont H, Day IN, Nadeem Khan M, Lovestone S, McCulley M, Morris CM, Munoz DG, O'Brien K, Russ C, Del Ser T, Warden D: Rate of progression of cognitive decline in Alzheimer's disease: effect of butyrylcholinesterase K gene variation. J Neurol Neurosurg Psychiatry 2005;76:640-643.